Bexorg, Inc. Secures $20M Seed Round to Revolutionize CNS Drug Discovery with Its Breakthrough BrainEx Platform

Bexorg, Inc. is excited to announce that it has successfully raised $20,000,000 in its latest funding round, marking a pivotal milestone in the company’s journey to transform CNS drug discovery and development. As a privately held techbio company, Bexorg has already distinguished itself by launching the first-ever full tech stack platform specifically designed to support drug discovery and development in the human brain—a breakthrough that opens untapped opportunities in neuroscience research. The funds will be instrumental in expanding the reach and capabilities of its proprietary whole-brain perfusion technology, which is revolutionizing the study of brain connectivity, circuit function, and disease processes. With this innovative approach, researchers can now identify novel targets, biomarkers, and evaluate the effectiveness of therapeutics for neurological disorders before they advance to clinical trials. These resources will further bolster the development and application of the BrainEx platform, which generates high-fidelity human brain molecular datasets that power the XO Digital application. This AI and machine learning-centered engine is already making significant strides in accelerating discovery and development pipelines within the CNS space. In alignment with its commitment to ethical research practices—demonstrated through its collaboration with the NIH and its independent board of bioethics leaders—Bexorg will also use the new investment to deepen strategic partnerships with leading neuroscience companies. These collaborations are designed to integrate its revolutionary technology into CNS clinical programs and advance its in-house neurodegeneration assets. Ultimately, the funding will catalyze new levels of innovation in therapeutic development for neurological disorders, heralding a new era of possibility in brain science and patient care.